Airway inflammation enhances the effectiveness of elexacaftor-tezacaftor-ivacaftor therapy for cystic fibrosis and CFTR N1303K mutation.
November 1, 2024
Gentzsch M, Esther CR Jr, Ribeiro CMP. Lancet Respir Med. Nov 2024;12:e67.DOI: 10.1016/S2213-2600(24)00305-9. PMID: 39395437.